AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Cgm findings vs2/15/2024 ![]() ![]() Ĭhronic hyperglycemia increases risk for microvascular and macrovascular complications, as well as resultant increased morbidity and mortality in T1D. LAI is administered once or twice daily to inhibit gluconeogenesis and ketogenesis and RAI is administered multiple times per day to correct acute hyperglycemia and/or with meals to prevent hyperglycemia from carbohydrate intake. Injection therapy combines long-acting insulin (LAI, also referred to as basal insulin) and short- or rapid-acting insulin (RAI) to create a multiple daily injection (MDI) regimen. Insulin is administered subcutaneously via injection with a syringe or pen or via infusion with an insulin pump. T1D is a result of permanent autoimmune destruction of insulin-producing pancreatic β-cells leading to an absolute insulin deficiency, and thus requires treatment with insulin for the remainder of the lifetime. Currently, 1.6 million people are estimated to have T1D in the USA and this figure is predicted to increase to 5 million people by the year 2050. CSII also significantly increased TIR with no difference between groups.Ĭontinuous glucose monitoring (CGM) Continuous subcutaneous insulin infusion (CSII) Glycemic variability Type 2 diabetes U-500.Type 1 diabetes (T1D) is the most common form of diabetes in the pediatric population but is diagnosed in all ages, and incidence rates are continuing to rise. Conclusions: In the VIVID CGM substudy of U-500R in people with T2D requiring high doses of insulin, participants using CSII significantly reduced GV compared with MDI. There were no significant between-group differences in the endpoint mean glucose or A1C. TIR 70-180 mg/dL glucose increased significantly from baseline in the CSII group only, from 59.8% to 73.1% (change +12.9%, P < 0.05), but was not significantly different between groups. The CSII group had a significantly greater reduction from baseline in mean SD w of glucose (45.0 to 38.2 mg/dL ) compared with the MDI group (47.0 to 45.8 P = 0.047). Results: Of 54 participants enrolled, 41 with evaluable data were analyzed (17 and 24 in CSII and MDI groups, respectively). The primary objective was to compare GV between CSII and MDI groups, based on change from baseline of within-day standard deviation (SD w) of CGM glucose. Participants performed masked CGM for seven consecutive days on each of three occasions: before weeks 0 (baseline), 14, and 26. Methods: VIVID participants were adults who had insulin requirements of >200 but ≤600 U/day and A1C 7.5% to 12%. To assess glycemic variability (GV) and time in range (TIR), a subset of participants performed masked continuous glucose monitoring (CGM). Background: The E Valuating U-500R Infusion Versus Injection in Type 2 Diabetes Mellitus (VIVID) study compared two methods of U-500R insulin delivery, continuous subcutaneous insulin infusion (CSII) and multiple daily injection (MDI), for 26 weeks in people with type 2 diabetes (T2D) requiring high doses of insulin.
0 Comments
Read More
Leave a Reply. |